Methods of administering anti-TNFalpha antibodies

摘要

METHODS OF ADMINISTERING ANTI-TNFa ANTIBODIES Abstract Methods of treating disorders in which TNFa activity is detrimental via 5 biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a(hTNFa) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFa (e.g., Kd = 10~8 M or less), a slow off rate for hTNFa dissociation (e.g., Korr = 10 3 sec -l or less) and neutralize hTNFca activity in vitro io and in vivo. An antibody of the invention can be a full-length antibody or an antigen binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.